灌注加权动脉自旋标记鉴别高级别胶质瘤进展性疾病与治疗诱发效应
这项回顾性单中心队列研究纳入141例高级别胶质瘤患者共173个病灶,评估动脉自旋标记灌注在鉴别进展性疾病与治疗诱发效应中的价值。视觉分析显示,放疗后3个月内OR为0.65,3至6个月为3.5,6个月后为6.8;AUC分别为0.456、0.652和0.719。结论认为动脉自旋标记在放疗后6个月内鉴别能力差,此后尚可,可能需要结合其他影像特征和临床信息。
要点
- 放疗后6个月内动脉自旋标记视觉鉴别进展性疾病与治疗诱发效应能力差,6个月后尚可。
- 视觉分析中,放疗后6个月后动脉自旋标记阳性提示进展性疾病的OR为6.8(95%CI 1.48-32,P=.014)。
- 定量分析各时间段AUC均较低(0.520、0.588、0.587),鉴别价值有限。
核心结论
- 动脉自旋标记在高级别胶质瘤放疗后6个月内鉴别进展性疾病与治疗诱发效应表现差,此后表现尚可;可能需要结合其他影像特征和临床信息以提高鉴别能力。
研究设计与样本
- 回顾性单中心队列研究,连续纳入2012年1月1日至2018年12月31日诊断的高级别胶质瘤成人患者,放疗伴或不伴化疗后出现新发或增大的强化病灶且行动脉自旋标记检查,共141例患者173个病灶,中位年龄63岁;动脉自旋标记为常规随访检查的一部分;结局通过组织学或大于6周的影像学随访定义;由两名神经放射科医生进行视觉分级和定量分析。
关键影像表现/征象
- 视觉分析将动脉自旋标记分为阴性(低于灰质信号)或阳性(等/高于灰质信号),并定量比较强化病灶与对侧正常脑组织的信号强度。
- 94个(54%)病灶为治疗诱发效应,79个(46%)为进展性疾病。
- 放疗后3个月内、3至6个月、6个月后视觉分析动脉自旋标记阳性提示进展性疾病的OR分别为0.65(95%CI 0.28-1.51,P=.319)、3.5(95%CI 0.69-17.89,P=.132)、6.8(95%CI 1.48-32,P=.014)。
- 视觉分析相应AUC分别为0.456、0.652、0.719;定量分析AUC分别为0.520、0.588、0.587。
- 观察者间和观察者内信度系数分别为0.67和0.62。
诊断标准与关键数值
- 视觉分级标准:动脉自旋标记信号低于灰质为阴性,等/高于灰质为阳性。
- 放疗后6个月后视觉分析动脉自旋标记阳性提示进展性疾病的OR为6.8(95%CI 1.48-32,P=.014),AUC为0.719。
- 放疗后3至6个月视觉分析OR为3.5(95%CI 0.69-17.89,P=.132),AUC为0.652。
- 放疗后3个月内视觉分析OR为0.65(95%CI 0.28-1.51,P=.319),AUC为0.456。
- 定量分析AUC在3个月内、3至6个月、6个月后分别为0.520、0.588、0.587。
临床应用与阅片要点
- 动脉自旋标记在放疗后6个月内鉴别进展性疾病与治疗诱发效应表现差,6个月后表现尚可。
- 作者认为动脉自旋标记可能需要结合其他影像特征和临床信息以提高鉴别能力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Treatment-induced effects are difficult to differentiate from progressive disease in radiologically progressing diffuse gliomas after treatment. This retrospective, single-center cohort study investigated the diagnostic value of arterial spin-labeling perfusion in differentiating progressive disease from treatment-induced effects in irradiated patients with a high-grade glioma.
MATERIALS AND METHODS: Adults with a high-grade glioma diagnosed between January 1, 2012, and December 31, 2018, with a new or increasing contrast-enhancing lesion after radiotherapy with or without chemotherapy and arterial spin-labeling were consecutively included. Arterial spin-labeling is part of the routine follow-up examinations of patients with a high-grade glioma. The outcomes of progressive disease or treatment-induced effects were defined after histologic or >6 weeks radiologic follow-up. Two neuroradiologists graded the arterial spin-labeling visually as negative (hypointense to gray matter) or positive (iso-/hyperintense). Additionally, the arterial spin-labeling signal intensity in the enhancing lesion was compared quantitatively with that in the contralateral normal brain. Diagnostic test properties and the Cohen κ inter- and intrarater reliability were determined. We present data according to the time after radiation therapy.
RESULTS: We included 141 patients with 173 lesions (median age, 63 years). Ninety-four (54%) lesions showed treatment-induced effects, and 79 (46%), progressive disease. For visual analysis, the ORs of an arterial spin-labeling positive for progressive disease in the group with progression within 3, between 3 and 6, and after 6 months after radiation therapy were 0.65 (95% CI, 0.28-1.51; P = .319), 3.5 (95% CI, 0.69-17.89; P = .132), and 6.8 (95% CI, 1.48-32; P = .014). The areas under the curve were 0.456, 0.652, and 0.719. In quantitative analysis, the areas under the curve were 0.520, 0.588, and 0.587 in these groups. Inter- and intrarater reliability coefficients were 0.67 and 0.62.
CONCLUSIONS: Arterial spin-labeling performed poorly in differentiating progressive disease from treatment-induced effects in high-grade gliomas within 6 months after radiation therapy, with fair performance after this period. Arterial spin-labeling may need to be combined with other imaging features and clinical information for better performance.
引用
- Flies CM, Snijders TJ, De Leeuw BI, et al. The Differentiation between Progressive Disease and Treatment-Induced Effects with Perfusion-Weighted Arterial Spin-Labeling in High-Grade Gliomas. AJNR Am J Neuroradiol. 2024. PMID: 38871374. doi:10.3174/ajnr.A8336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。